I at least prefer a heads up on when they will address things...I am sure the additional exposure recently is a double edged sword given the size of the company...patient interest, biopharma interest, investor interest...it's like they say with those tip lines for cases...you appreciate the interest but it can become difficult to prioritize what to follow up on first.

Here's to hoping Thursday has all that we've been waiting for!